SeaStar Medical Holding Corpora ICU

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
31/100
Developing

Ranked against 712 peers in Biotechnology

About SeaStar Medical Holding Corpora

SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for … Full ICU analysis →

Key risks

  • ROIC Below WACC or Peers ROIC at 34.5th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.21), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
25
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where ICU ranks in Biotechnology

SeaStar Medical Holding Corpora ranks #503 of 713 scored companies in Biotechnology by moat score — the top 71%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
499 OKYO Pharma Limited OKYO 31/100 Developing
500 Passage Bio, Inc. PASG 31/100 Developing
501 Precigen, Inc. PGEN 31/100 Developing
502 GlycoMimetics, Inc. GLYC 31/100 Developing
503 SeaStar Medical Holding Corpora ICU 31/100 Developing
504 ICUCW ICUCW 31/100 Developing
505 Onconetix, Inc. ONCO 31/100 Developing
506 Cabaletta Bio, Inc. CABA 31/100 Developing
507 Werewolf Therapeutics, Inc. HOWL 31/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How ICU scores on the Corporate Default defenses

Pricing Power

Score 25 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 39 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 38 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 17 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 31 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 50 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ICU's moat

What is SeaStar Medical Holding Corpora's moat score?

SeaStar Medical Holding Corpora (ICU) scores 31 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #503 of 713 scored companies in Biotechnology, the top 71%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (50/100) and its weakest is Capital Efficiency (17/100).

How does SeaStar Medical Holding Corpora compare with other Biotechnology companies?

SeaStar Medical Holding Corpora ranks #503 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are GlycoMimetics, Inc. (GLYC) at 31 just above it and ICUCW (ICUCW) at 31 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is SeaStar Medical Holding Corpora scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for SeaStar Medical Holding Corpora?

The Corporate Default template measures 6 defenses, and ICU scores: Pricing Power (25), Cost Advantage (39), Customer Stickiness (38), Capital Efficiency (17), Resilience (31), Scale & Market Position (50). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000